The National Melanoma Research Registry: a fundamental for disease characterization and epidemiology

Date

21 Oct 2018

Session

Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Presenters

Femida Gwadry-Sridhar

Citation

Annals of Oncology (2018) 29 (suppl_8): viii442-viii466. 10.1093/annonc/mdy289

Authors

F. Gwadry-Sridhar1, H. McConkey2, X. Teng3, D.S. Ernst4

Author affiliations

  • 1 Informatics, Pulse infoframe Inc., N6G 4X8 - London/CA
  • 2 Research Coordinator, Global Melanoma Research Network, N6C 2R6 - London/CA
  • 3 Data Science, Pulse Infoframe Inc., London/CA
  • 4 Dept Of Oncology, London Regional Cancer Program, N6A4L6 - London/CA
More

Resources

Background

Approximately 7200 Canadians are diagnosed with primary melanoma each year resulting in 1240 deaths. While the advent of new treatment provides hope, the emergence of precision medicine requires genomic data and clinical trials benefit from real-world data. To avail of these advances, a better understanding of both disease characterization and the impact of treatment on both clinical endpoints and patient reported outcomes is necessary to assess morbidity and mortality. We initiated a Pan-Canadian Melanoma Research Network (CMRN) in 2010 to collect both clinical and patient reported data.

Methods

The CMRN collects data retrospectively and prospectively from ten cancer centers in Ontario, Alberta and Quebec. The data dictionary includes 250 disease specific variables collected to produce structured data, including stage, pathology, tumour mutation types, time from primary diagnosis to recurrence, sites of metastases, and lines of treatment. Outcomes such as metastasis free interval, quality of life and survival and performance status are collected.

Results

3016 patients (pts) have consented to this registry. 11% pts are < 50 years; 42% pts are 41-70 years; whereas 47% pts are > 71 years. 58% are male and 42% are female. 67% of pts presented with Stage I or II melanoma, and 33% presented with Stage III or IV. Of pts with known primary histology, 73% were classified as superficial spreading or nodular (36.5% each). Of the 589 pts who received mutation testing, 51% were found to have a BRAF mutation. Interferon treatment accounted for 80% of adjuvant therapies, whereas < 3% were checkpoint inhibitors or targeted therapies. 931 pts received metastatic systemic treatment. 14% of 1st line treatments were targeted therapies, whereas 18% were checkpoint inhibitors. 49% of metastatic patients received a 2nd line treatment, with checkpoint inhibitors and targeted therapies accounting for 65% and 10%, respectively.

Conclusions

This CMRN allows for detailed analysis of both patient and disease characteristics, providing a key tool for future research. This network is still expanding to include additional provinces and continues to conduct real-world research to advance care and improve outcomes.

Clinical trial identification

Legal entity responsible for the study

Global Melanoma Research Network.

Funding

Global Melanoma Research Network.

Editorial Acknowledgement

Disclosure

All authors have declared no conflicts of interest.

Resources from the same session

Volume reduction rate of the primary tumor of esophageal squamous cell carcinoma after neoadjuvant chemotherapy: Could this measurement be a surrogate end point for survival before surgery?

Presenter: Shinsuke Nagasawa

Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Resources:

Abstract

Utility of Carcinoembryonic Antigen (CEA) in Appendiceal carcinoma

Presenter: ASHA KARIPPOT

Session: Poster display session: Basic science, Endocrine tumours, Gastrointestinal tumours - colorectal & non-colorectal, Head and neck cancer (excluding thyroid), Melanoma and other skin tumours, Neuroendocrine tumours, Thyroid cancer, Tumour biology & pathology

Resources:

Abstract

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings